Correction: Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness (Clinical Pharmacokinetics, (2026), 65, 4, (621-632), 10.1007/s40262-025-01610-4)

Yan Wang; Laura H. Bukkems; Rob ter Heine; J. G.C. van Hasselt; S. L.W. Koolen; J. J.M.A. Hendrikx; Tom Van der Hulle; Ellen Kapiteijn; Juliette Zwaveling; Annemarie Becker; Michel M. van den Heuvel; Willemijn S.M.E. Theelen; Thijs H. Oude Munnink; Egbert F. Smit; Henk Jan Guchelaar; Dirk Jan A.R. Moes

doi:10.1007/s40262-026-01649-x

Correction: Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness (Clinical Pharmacokinetics, (2026), 65, 4, (621-632), 10.1007/s40262-025-01610-4)

Yan Wang
, Laura H. Bukkems
, Rob ter Heine
, J. G.C. van Hasselt
, S. L.W. Koolen
, J. J.M.A. Hendrikx
, Tom Van der Hulle
, Ellen Kapiteijn
, Juliette Zwaveling
, Annemarie Becker
, Michel M. van den Heuvel
, Willemijn S.M.E. Theelen
, Thijs H. Oude Munnink
, Egbert F. Smit
, Henk Jan Guchelaar
, Dirk Jan A.R. Moes^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

In this article the sentence “Forty-six percent of the participants were male” was incorrect and should have read “One-hundred percent of the participants were male (higher nivolumab clearance compared to females).” In Table 1 of this article, the data in the section “Sex, n (%)” were incorrect and should have been as provided below. Table 1 Demographic characteristics of virtual patient population (N = 500) (Table presented.) N = 500 Sex, n (%) Male 232 (46%) Female 268 (54%) Age, median (range), years 64 (27–85) Weight, median (range), kg 67 (31–128) Height, median (range), cm 166 (142–194) N number of patients Table 1 Demographic characteristics of virtual patient population (N = 500) (Table presented.) N = 500 Sex, n (%) Male 500 (100%) Age, median (range), years 64 (27–85) Weight, median (range), kg 67 (31–128) Height, median (range), cm 166 (142–194) N number of patients The original article has been corrected.

Original language	English
Pages (from-to)	1113-1114
Number of pages	2
Journal	Clinical Pharmacokinetics
Volume	65
Issue number	7
Early online date	19 May 2026
DOIs	https://doi.org/10.1007/s40262-026-01649-x
Publication status	Published - Jul 2026

Access to Document

10.1007/s40262-026-01649-xLicence: CC BY-NC

s40262-026-01649-xFinal published version, 391 KBLicence: CC BY-NC

Cite this

Wang, Y., Bukkems, L. H., ter Heine, R., van Hasselt, J. G. C., Koolen, S. L. W., Hendrikx, J. J. M. A., Van der Hulle, T., Kapiteijn, E., Zwaveling, J., Becker, A., van den Heuvel, M. M., Theelen, W. S. M. E., Oude Munnink, T. H., Smit, E. F., Guchelaar, H. J., & Moes, D. J. A. R. (2026). Correction: Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness (Clinical Pharmacokinetics, (2026), 65, 4, (621-632), 10.1007/s40262-025-01610-4). Clinical Pharmacokinetics, 65(7), 1113-1114. https://doi.org/10.1007/s40262-026-01649-x

@article{907a8d0011144f299a35d108951e4219,

title = "Correction: Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness (Clinical Pharmacokinetics, (2026), 65, 4, (621-632), 10.1007/s40262-025-01610-4)",

abstract = "In this article the sentence “Forty-six percent of the participants were male” was incorrect and should have read “One-hundred percent of the participants were male (higher nivolumab clearance compared to females).” In Table 1 of this article, the data in the section “Sex, n (\%)” were incorrect and should have been as provided below. Table 1 Demographic characteristics of virtual patient population (N = 500) (Table presented.) N = 500 Sex, n (\%) Male 232 (46\%) Female 268 (54\%) Age, median (range), years 64 (27–85) Weight, median (range), kg 67 (31–128) Height, median (range), cm 166 (142–194) N number of patients Table 1 Demographic characteristics of virtual patient population (N = 500) (Table presented.) N = 500 Sex, n (\%) Male 500 (100\%) Age, median (range), years 64 (27–85) Weight, median (range), kg 67 (31–128) Height, median (range), cm 166 (142–194) N number of patients The original article has been corrected.",

author = "Yan Wang and Bukkems, \{Laura H.\} and \{ter Heine\}, Rob and \{van Hasselt\}, \{J. G.C.\} and Koolen, \{S. L.W.\} and Hendrikx, \{J. J.M.A.\} and \{Van der Hulle\}, Tom and Ellen Kapiteijn and Juliette Zwaveling and Annemarie Becker and \{van den Heuvel\}, \{Michel M.\} and Theelen, \{Willemijn S.M.E.\} and \{Oude Munnink\}, \{Thijs H.\} and Smit, \{Egbert F.\} and Guchelaar, \{Henk Jan\} and Moes, \{Dirk Jan A.R.\}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2026.",

year = "2026",

month = jul,

doi = "10.1007/s40262-026-01649-x",

language = "English",

volume = "65",

pages = "1113--1114",

journal = "Clinical Pharmacokinetics",

issn = "0312-5963",

publisher = "Adis",

number = "7",

}

Wang, Y, Bukkems, LH, ter Heine, R, van Hasselt, JGC, Koolen, SLW, Hendrikx, JJMA, Van der Hulle, T, Kapiteijn, E, Zwaveling, J, Becker, A, van den Heuvel, MM, Theelen, WSME, Oude Munnink, TH, Smit, EF, Guchelaar, HJ & Moes, DJAR 2026, 'Correction: Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness (Clinical Pharmacokinetics, (2026), 65, 4, (621-632), 10.1007/s40262-025-01610-4)', Clinical Pharmacokinetics, vol. 65, no. 7, pp. 1113-1114. https://doi.org/10.1007/s40262-026-01649-x

Correction: Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness (Clinical Pharmacokinetics, (2026), 65, 4, (621-632), 10.1007/s40262-025-01610-4). / Wang, Yan; Bukkems, Laura H.; ter Heine, Rob et al.
In: Clinical Pharmacokinetics, Vol. 65, No. 7, 07.2026, p. 1113-1114.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Correction

T2 - Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness (Clinical Pharmacokinetics, (2026), 65, 4, (621-632), 10.1007/s40262-025-01610-4)

AU - Wang, Yan

AU - Bukkems, Laura H.

AU - ter Heine, Rob

AU - van Hasselt, J. G.C.

AU - Koolen, S. L.W.

AU - Hendrikx, J. J.M.A.

AU - Van der Hulle, Tom

AU - Kapiteijn, Ellen

AU - Zwaveling, Juliette

AU - Becker, Annemarie

AU - van den Heuvel, Michel M.

AU - Theelen, Willemijn S.M.E.

AU - Oude Munnink, Thijs H.

AU - Smit, Egbert F.

AU - Guchelaar, Henk Jan

AU - Moes, Dirk Jan A.R.

PY - 2026/7

Y1 - 2026/7

N2 - In this article the sentence “Forty-six percent of the participants were male” was incorrect and should have read “One-hundred percent of the participants were male (higher nivolumab clearance compared to females).” In Table 1 of this article, the data in the section “Sex, n (%)” were incorrect and should have been as provided below. Table 1 Demographic characteristics of virtual patient population (N = 500) (Table presented.) N = 500 Sex, n (%) Male 232 (46%) Female 268 (54%) Age, median (range), years 64 (27–85) Weight, median (range), kg 67 (31–128) Height, median (range), cm 166 (142–194) N number of patients Table 1 Demographic characteristics of virtual patient population (N = 500) (Table presented.) N = 500 Sex, n (%) Male 500 (100%) Age, median (range), years 64 (27–85) Weight, median (range), kg 67 (31–128) Height, median (range), cm 166 (142–194) N number of patients The original article has been corrected.

AB - In this article the sentence “Forty-six percent of the participants were male” was incorrect and should have read “One-hundred percent of the participants were male (higher nivolumab clearance compared to females).” In Table 1 of this article, the data in the section “Sex, n (%)” were incorrect and should have been as provided below. Table 1 Demographic characteristics of virtual patient population (N = 500) (Table presented.) N = 500 Sex, n (%) Male 232 (46%) Female 268 (54%) Age, median (range), years 64 (27–85) Weight, median (range), kg 67 (31–128) Height, median (range), cm 166 (142–194) N number of patients Table 1 Demographic characteristics of virtual patient population (N = 500) (Table presented.) N = 500 Sex, n (%) Male 500 (100%) Age, median (range), years 64 (27–85) Weight, median (range), kg 67 (31–128) Height, median (range), cm 166 (142–194) N number of patients The original article has been corrected.

UR - https://www.scopus.com/pages/publications/105039704513

U2 - 10.1007/s40262-026-01649-x

DO - 10.1007/s40262-026-01649-x

M3 - Comment/Letter to the editor

C2 - 42154177

AN - SCOPUS:105039704513

SN - 0312-5963

VL - 65

SP - 1113

EP - 1114

JO - Clinical Pharmacokinetics

JF - Clinical Pharmacokinetics

IS - 7

ER -

Wang Y, Bukkems LH, ter Heine R, van Hasselt JGC, Koolen SLW, Hendrikx JJMA et al. Correction: Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness (Clinical Pharmacokinetics, (2026), 65, 4, (621-632), 10.1007/s40262-025-01610-4). Clinical Pharmacokinetics. 2026 Jul;65(7):1113-1114. Epub 2026 May 19. doi: 10.1007/s40262-026-01649-x

Correction: Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness (Clinical Pharmacokinetics, (2026), 65, 4, (621-632), 10.1007/s40262-025-01610-4)

Abstract

Access to Document

Other files and links

Fingerprint

Model-Based Alternative Dosing Strategies for Subcutaneous Nivolumab to Improve Cost Effectiveness

Cite this